Implications for Cost, Care Quality, and Employee Engagement

At-home diagnostic testing has shifted from a convenience to a standard part of healthcare delivery. Accelerated by COVID-19 and advances in digital health, home diagnostics now include infectious disease testing, chronic condition monitoring, cancer screening, fertility, and genetics. For employers and plan fiduciaries, the focus is no longer whether these tools will remain relevant, but how to use them effectively to improve outcomes, manage costs, and avoid overutilization.

Evidence shows that evidence-based home tests can increase preventive screening rates, improve chronic disease management, expand access to care, and reduce downstream medical costs. However, poorly managed use can lead to false positives, unnecessary follow-up care, employee anxiety, and increased spending.

This article examines where home diagnostics provide value, where caution is needed, and how employers, carriers, and TPAs should approach coverage and employee engagement.

The Current Landscape

Home diagnostics are not new. Pregnancy tests have been available since the late 1970s, but the COVID-19 pandemic normalized self-testing at scale. In early 2022, more than 40 million U.S. households used government-supplied at-home COVID-19 tests, with approximately one-third of households participating overall (CDC, 2023). Adoption was widespread, and access gaps narrowed across racial and ethnic groups.

Industry forecasts indicate continued growth. A 2025 global diagnostics survey found that more than 60% of experts expect 10% to 25% of diagnostic tests to be performed at home by 2035, with U.S. adoption expected to outpace Europe (Simon-Kucher, 2025). Growth is strongest in chronic disease monitoring, women’s health, infectious disease testing, and cardiovascular screening. Several categories of home diagnostics are already producing measurable results.

Cancer Screening

Mailed fecal immunochemical test (FIT) kits and FIT-DNA tests, such as Cologuard, improve screening adherence compared with office-based colonoscopy programs alone. A large Kaiser Permanente initiative that mailed annual FIT kits more than doubled screening rates, reduced colorectal cancer incidence by approximately 30%, and cut deaths by half while eliminating racial disparities in screening outcomes (Kaiser Permanente Division of Research, 2025). For employers, these outcomes may reduce catastrophic claims, support earlier intervention, and improve workforce health. Coverage of guideline-recommended home screening tests is considered high-value preventive care.

Infectious Disease Testing

At-home COVID-19 tests demonstrated the value of rapid, decentralized diagnostics. Similar models are now emerging for influenza, RSV, and combination respiratory panels. While home antigen tests are generally less sensitive than laboratory PCR testing, their speed and accessibility can improve real-world detection and support faster behavior changes, particularly when paired with telehealth follow-up.

Chronic Disease Monitoring

Home monitoring tools, including blood pressure monitors and continuous glucose monitors (CGMs), are associated with reductions in emergency visits, hospitalizations, and long-term complications for individuals managing hypertension and diabetes. These tools may be most effective for populations with low adherence to treatment plans or preventive care.

However, broad implementation across already compliant populations may increase plan costs without producing meaningful clinical improvement. Employers should evaluate where these tools are likely to generate measurable value rather than assuming universal deployment will reduce spending.

Direct-to-Consumer Genetic and Wellness Testing

Direct-to-consumer genetic tests and wellness panels present mixed value for employer-sponsored health plans. While FDA-authorized genetic health risk tests, including certain 23andMe reports, meet analytical standards, results are probabilistic rather than diagnostic and are often misunderstood without clinical guidance (FDA, 2017; Harvard Health, 2023).

False positives and ambiguous findings can increase employee anxiety and lead to unnecessary follow-up testing. Physicians have also raised concerns that repeated self-testing may contribute to a cycle of anxiety, confirmatory diagnostics, and low-value care (Becker’s Hospital Review, 2024). Without utilization controls and employee education, employer health plans may see higher laboratory and imaging costs rather than savings.

Employer Implications

Self-insured employers should view home diagnostic testing as one component of a broader population health and cost-management strategy. When implemented appropriately, these tools can support higher preventive screening rates, earlier disease detection, improved chronic disease management, and lower hospitalization and late-stage treatment costs.

The key is using employer-specific data to identify gaps in care within the covered population. When gaps exist, employers should encourage evidence-based screening tools that align with established clinical guidelines and produce measurable outcomes. High-value tests should be covered at low or no cost to members, with minimal barriers to follow-up care when additional screenings or diagnostics are required. Employers should also work with carriers, TPAs, and clinical partners to evaluate new opportunities regularly, as innovation in this space is advancing quickly and benefit strategies will need to adapt.

Home diagnostic testing should not be viewed as a fringe benefit or consumer trend. It is becoming part of the healthcare system. When integrated into a disciplined benefits strategy, these tools can improve employee experience and support long-term cost control. Without appropriate oversight, they can also increase unnecessary utilization and spending.

Sources:
– Centers for Disease Control and Prevention (CDC). Use of COVIDTests.gov At-Home Test Kits Among Adults, MMWR, 2023. https://www.cdc.gov/mmwr/volumes/72/wr/mm7201a4.htm
– Simon-Kucher. From Pandemic Spike to Permanent Shift: The Rise of At-Home Diagnostics, 2025. https://www.simon-kucher.com
– Kaiser Permanente Division of Research. Colorectal Cancer Screening Program Doubled Screening Rates and Halved Deaths, 2025. https://divisionofresearch.kaiserpermanente.org
– U.S. Food and Drug Administration (FDA). Information Regarding the OraQuick In-Home HIV Test.
https://www.fda.gov
– U.S. Food and Drug Administration (FDA). FDA Allows Marketing of First Direct-to-Consumer Genetic Health Risk Tests, 2017.
https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-direct-consumer-tests-provide-genetic-risk-information-certain
– Wang et al. Trends in Continuous Glucose Monitor Use Among Adults With Diabetes, Journal of General Internal Medicine, 2024/2025.
– UW Medicine / JAMA Network Open. Steady Glucose Monitor Use Helps Blood Sugar Control, 2025.
https://newsroom.uw.edu
– Cappuccio et al. Blood Pressure Control by Home Monitoring: Meta-Analysis of Randomized Trials, BMJ.
https://www.bmj.com
– Harvard Health Publishing. At-Home Tests: Help or Hindrance?, 2023.
https://www.health.harvard.edu
– Becker’s Hospital Review. At-Home Tests Are Booming, but Physicians Have Concerns, 2024.
https://www.beckershospitalreview.com
– Deloitte Insights. The Diagnostics Industry of Tomorrow, 2023.
https://www2.deloitte.com/us/en/insights/industry/health-care/future-of-diagnostics.html